|Day Low/High||67.51 / 69.57|
|52 Wk Low/High||62.88 / 104.47|
SAN RAFAEL, Calif., Oct.
The SPDR S&P Biotech ETF, Alexion Pharmaceuticals and BioMarin Pharmaceuticals set up nicely for this options strategy.
BMN 307 Represents a Potential 3rd PKU Treatment Option in BioMarin's PKU Franchise
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
- Total Revenues of $387.8 million in the Quarter
SAN RAFAEL, Calif., July 16, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., July 9, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.
Sangamo's stock price is surging after a pair of patients reported no bleeding events for as long as 24 weeks following treatment following investigational SB-525 gene therapy for severe hemophilia A.
Potential 1st Marketing Application for a Gene Therapy Product in Any Type of Hemophilia to be Reviewed by Health Authorities
Abstract Covers Efficacy and Safety of AAV Gene Therapy Over 3 Years with Valoctocogene Roxaparvovec in Severe Hemophilia A
European Commission Approval Triggers $15 Million Payment
The names include a veterinary drug concern plus companies with successful drugs on the market.
Company Announces Enrollment Met for 2-5 Year-Old Cohort in Separate Phase 2 Study in Infants and Young Children
SAN RAFAEL, Calif., June 5, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.
First and Only Treatment in China Approved for Patients with This Ultra-Rare Genetic Condition
Timing of Regulatory Submissions to Be Determined in 3Q 2019
Substantial Reduction in excess of 92% in Mean Bleed Rate Requiring Factor VIII Infusions; Sustained over the Period of Observation (3 Years in High Dose and 2 Years in Low Dose)
SAN RAFAEL, Calif., May 27, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., May 16, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.
These 'Bearish Bets' are showing both technical and quantitative deterioration.
BMRN, SFIX, INGR, VC and IQV all recently were downgraded by TheStreet's Quant Ratings.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGTC, DCO, HAE, LILA, LILAK, NRT, RCII Downgrades: ANDE, BMRN, CCO, CLH, HCP, HGV, HIIQ, INGR, NCMI, NHTC Initiations: FEDU Read on to get TheStreet Quant Ratings' detailed report:
I am incrementally using buy-write option orders to add some shares to core holdings.
SAN RAFAEL, Calif., May 8, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.
First Enzyme Substitution Therapy Approved in Europe to Treat the Underlying Cause of PKU in Patients Aged 16 Years or Older at Doses up to 60 mg
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.